Graft-versus-host disease treatment

Predictors of survival

John E. Levine, Brent Logan, Juan Wu, Amin M. Alousi, Vincent Ho, F Javier Bolanos Meade, Daniel Weisdorf

Research output: Contribution to journalArticle

Abstract

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplant (HCT) is the major reason for nonrelapse mortality (NRM), and thus is a major determinant of long-term survival. Clinical trials of new aGVHD treatments are needed to identify approaches that will ultimately improve upon HCT survival. At present, it is not clear how quickly response to GVHD treatment needs to be established to reliably categorize patients at high risk for death or to promptly identify those who might benefit from alternate treatment. Therefore, we analyzed time to response from onset of aGVHD treatment in 180 patients who were enrolled on a national, randomized, phase II aGVHD treatment clinical trial whose initial treatment of GVHD consisted of high-dose steroids plus a second immunosuppressive agent. The aim of this analysis was to determine whether time to aGVHD treatment response predicts patient outcomes, especially survival. We used response at 14, 28, and 56 days from initiation of aGVHD treatment to categorize patients for NRM and survival. Multivariate analyses and specificity/sensitivity analyses identified that day 28 response (complete or partial response) best categorized patients by NRM and survival at 9 months from start of aGVHD treatment. If verified as a reliable predictor of late outcomes following other aGVHD treatment approaches, day 28 response should serve as a standard early endpoint for future trials of aGVHD therapy.

Original languageEnglish (US)
Pages (from-to)1693-1699
Number of pages7
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume16
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Graft vs Host Disease
Survival
Therapeutics
Mortality
Clinical Trials
Transplants
Immunosuppressive Agents
Cell Survival
Multivariate Analysis
Steroids
Sensitivity and Specificity

Keywords

  • Allogeneic
  • BMT
  • GVHD
  • Prognosis
  • Response
  • Survival

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Graft-versus-host disease treatment : Predictors of survival. / Levine, John E.; Logan, Brent; Wu, Juan; Alousi, Amin M.; Ho, Vincent; Bolanos Meade, F Javier; Weisdorf, Daniel.

In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, Vol. 16, No. 12, 12.2010, p. 1693-1699.

Research output: Contribution to journalArticle

Levine, John E. ; Logan, Brent ; Wu, Juan ; Alousi, Amin M. ; Ho, Vincent ; Bolanos Meade, F Javier ; Weisdorf, Daniel. / Graft-versus-host disease treatment : Predictors of survival. In: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 12. pp. 1693-1699.
@article{17faf6a5e9a44b7187d1bf38fa21823e,
title = "Graft-versus-host disease treatment: Predictors of survival",
abstract = "Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplant (HCT) is the major reason for nonrelapse mortality (NRM), and thus is a major determinant of long-term survival. Clinical trials of new aGVHD treatments are needed to identify approaches that will ultimately improve upon HCT survival. At present, it is not clear how quickly response to GVHD treatment needs to be established to reliably categorize patients at high risk for death or to promptly identify those who might benefit from alternate treatment. Therefore, we analyzed time to response from onset of aGVHD treatment in 180 patients who were enrolled on a national, randomized, phase II aGVHD treatment clinical trial whose initial treatment of GVHD consisted of high-dose steroids plus a second immunosuppressive agent. The aim of this analysis was to determine whether time to aGVHD treatment response predicts patient outcomes, especially survival. We used response at 14, 28, and 56 days from initiation of aGVHD treatment to categorize patients for NRM and survival. Multivariate analyses and specificity/sensitivity analyses identified that day 28 response (complete or partial response) best categorized patients by NRM and survival at 9 months from start of aGVHD treatment. If verified as a reliable predictor of late outcomes following other aGVHD treatment approaches, day 28 response should serve as a standard early endpoint for future trials of aGVHD therapy.",
keywords = "Allogeneic, BMT, GVHD, Prognosis, Response, Survival",
author = "Levine, {John E.} and Brent Logan and Juan Wu and Alousi, {Amin M.} and Vincent Ho and {Bolanos Meade}, {F Javier} and Daniel Weisdorf",
year = "2010",
month = "12",
doi = "10.1016/j.bbmt.2010.05.019",
language = "English (US)",
volume = "16",
pages = "1693--1699",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Graft-versus-host disease treatment

T2 - Predictors of survival

AU - Levine, John E.

AU - Logan, Brent

AU - Wu, Juan

AU - Alousi, Amin M.

AU - Ho, Vincent

AU - Bolanos Meade, F Javier

AU - Weisdorf, Daniel

PY - 2010/12

Y1 - 2010/12

N2 - Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplant (HCT) is the major reason for nonrelapse mortality (NRM), and thus is a major determinant of long-term survival. Clinical trials of new aGVHD treatments are needed to identify approaches that will ultimately improve upon HCT survival. At present, it is not clear how quickly response to GVHD treatment needs to be established to reliably categorize patients at high risk for death or to promptly identify those who might benefit from alternate treatment. Therefore, we analyzed time to response from onset of aGVHD treatment in 180 patients who were enrolled on a national, randomized, phase II aGVHD treatment clinical trial whose initial treatment of GVHD consisted of high-dose steroids plus a second immunosuppressive agent. The aim of this analysis was to determine whether time to aGVHD treatment response predicts patient outcomes, especially survival. We used response at 14, 28, and 56 days from initiation of aGVHD treatment to categorize patients for NRM and survival. Multivariate analyses and specificity/sensitivity analyses identified that day 28 response (complete or partial response) best categorized patients by NRM and survival at 9 months from start of aGVHD treatment. If verified as a reliable predictor of late outcomes following other aGVHD treatment approaches, day 28 response should serve as a standard early endpoint for future trials of aGVHD therapy.

AB - Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplant (HCT) is the major reason for nonrelapse mortality (NRM), and thus is a major determinant of long-term survival. Clinical trials of new aGVHD treatments are needed to identify approaches that will ultimately improve upon HCT survival. At present, it is not clear how quickly response to GVHD treatment needs to be established to reliably categorize patients at high risk for death or to promptly identify those who might benefit from alternate treatment. Therefore, we analyzed time to response from onset of aGVHD treatment in 180 patients who were enrolled on a national, randomized, phase II aGVHD treatment clinical trial whose initial treatment of GVHD consisted of high-dose steroids plus a second immunosuppressive agent. The aim of this analysis was to determine whether time to aGVHD treatment response predicts patient outcomes, especially survival. We used response at 14, 28, and 56 days from initiation of aGVHD treatment to categorize patients for NRM and survival. Multivariate analyses and specificity/sensitivity analyses identified that day 28 response (complete or partial response) best categorized patients by NRM and survival at 9 months from start of aGVHD treatment. If verified as a reliable predictor of late outcomes following other aGVHD treatment approaches, day 28 response should serve as a standard early endpoint for future trials of aGVHD therapy.

KW - Allogeneic

KW - BMT

KW - GVHD

KW - Prognosis

KW - Response

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=78149414023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149414023&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.05.019

DO - 10.1016/j.bbmt.2010.05.019

M3 - Article

VL - 16

SP - 1693

EP - 1699

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -